What's New In Digital Health

Total body photography (TBP)—especially when paired with dermoscopy—helps clinicians do what matters most in melanoma surveillance: spot meaningful change over time. Recent evidence continues to support risk-adapted, digitally supported follow-up for high-risk patients, where frequent, consistent imaging can help move diagnoses toward earlier-stage disease.

Where 3D adds value is operational and clinical: faster capture, better visualization of curved surfaces/folds, and improved reproducibility between visits—the ingredients you need for reliable change detection at scale. A large prospective observational study of 1,274 high-risk patients using 3D-TBP + dermoscopy reported low number-needed-to-excise (3.26:1) and found that 46.5% of melanomas were detected without prior digital dermoscopy, suggesting 3D maps can help triage what truly needs dermoscopic attention.

AI should be treated as clinical decision support, not a replacement. In real-world testing, 3D CNNs reached high sensitivity (90%) but showed lower specificity than dermatologists, reinforcing the need for a clinician-in-the-loop workflow where AI flags change and the dermatologist (supported by trained imaging staff/specialists) makes the decision.

OptimaScan is designed around that reality: standardized automated capture (~1 minute), compact space needs, and DermEngine’s change-detection workflows—to turn “more images” into “more signal,” not more noise - keeping the specialist in the driver seat while leveraging their time and resources more efficiently.

Most dermatologists don’t need another technology pitch. They need tools that can do multiple things at once:

1. Improve clinical outcomes (earlier detection, smarter surveillance)
   
2. Protect workflow (standardization, less rework, with operationally sane protocols that do not blow up your schedule)
   
3. Scale with ease (it works in one office, with one provider—or across 20, 50,100+ sites with many providers)

That’s why the best conversation around 3D total body photography (3D-TBP) isn’t about “cool imaging.” It’s about whether a platform can help your team practice risk-adapted surveillance in a way that’s clinically responsible and operationally sustainable.

Let’s walk through some real questions behind that question—and what recent evidence says.

Will this actually improve early detection—or just create more noise?

TBP’s clinical promise is straightforward: create a high-quality baseline, then detect change at follow-ups. Educational and clinical resources consistently frame TBP as a way to identify new or changing lesions earlier than memory and narrative alone. The newer conversation is how to make change detection reliable in the real world.

A recent retrospective cohort study (2017–2024) supports a risk-adapted strategy, explicitly pointing toward intensified, digitally supported follow-up for higher-risk groups with screening approaches that reinforce a practical point: screening frequency and diagnostic method can influence the stage at diagnosis. Translation: the value rises when imaging is consistent, longitudinal, and built for repeatable comparisons—not a one-off “photo day.”

And 3D is increasingly being evaluated as a way to make that longitudinal comparison more reproducible (angles, folds, curved surfaces) and more efficient (capture speed).

2D vs 3D: is 3D worth it?

Here’s the practical difference most practices feel:

• Traditional 2D TBP can work well—but it often requires many photos, consistent positioning, and staff time. It’s effective, but it’s easy for operational variability to creep in.
  
• 3D TBP is designed to reduce those variables: faster capture, improved visualization, and a model that can support more consistent follow-ups.
  
  

The proof point that matters to a busy practice isn’t “3D is cool.” It’s outcomes and workflow.

A large prospective longitudinal observational study followed 1,274 high-risk patients using 3D-TBP + dermoscopy, reporting:

• 452 excisions in 322 patients
• 86 melanomas, plus BCC and SCC
  
• Number-needed-to-excise (NNE) of 3.26:1
• 46.5% of melanomas detected without prior digital dermoscopy
  
  

Why does that matter for your practice? Because it suggests 3D mapping can help you use dermoscopy and second-level tools where they’re most valuable, instead of forcing a “maximum dermoscopy for everyone” workflow just to stay safe.

"I heard 3D can increase excisions." How do we avoid that?

A common objection is real: “Won’t better imaging just lead to more biopsies and excisions?” In the same paper’s background discussion, the authors note randomized implementations where adding 3D-TBP + tele-review led to increased excisions and costs without improved melanoma detection, raising legitimate concerns about implementation.

This is exactly where the “AI + imaging + specialist” model matters. This isn’t an argument against 3D-TBP. It’s a warning about implementation.

When you increase visibility, you also increase the number of findings which is why your workflow needs to include prioritization, thresholds, and specialist oversight.

The practices that win with imaging are the ones that build guardrails and leverage the design intent behind DermEngine’s change-detection workflow:

• Standardized capture every time with OptimaScan (reduce noise and image variability)
  
• Longitudinal comparison tools to identify changes and prioritize differences by amount of change to support clinical decisions (identify meaningful change)
  
• A review model that keeps the dermatologist in control with detection sensitivity to review/edit matching results—so you can standardize thresholds across providers/sites
  
  

How does OptimaScan fit—especially versus legacy high-end systems?

Most large practices know the two historical options:

1. High-end, room-scale systems with major capital cost and space requirements
   
   
2. Traditional 2D capture that’s lower cost but labor intensive and difficult to standardize across many sites
   
   

The literature itself acknowledges a core barrier to broad 3D adoption: cost and substantial spatial requirements limiting access.

OptimaScan is positioned to change that equation for practices that want 3D benefits without the traditional operational burden.

The OptimaScan solution includes:

• ~1 minute capture
• 48MP capture using iPhone Pro / Pro Max models (15/16/17 supported)
• Compact footprint (80 cm x 80 cm x 225 cm), 200 kg weight limit, full 360° rotation
  
  

And the key point: it’s not just capture. It’s capture plus DermEngine’s workflow:

• MoleMatch for identifying new/changing spots and evolution tracking
  
• Lesion Matching that prioritizes change for review
  
• Enterprise-grade security posture (SOC 2, HIPAA/GDPR, regional data centers, audit controls)
  
• Patient engagement tools (secure sharing/portal access) that support retention
  
  

At $30k MSRP, the business conversation becomes very different: lower entry cost, faster time-to-value, and far less friction to deploy across multiple locations.

How do we pay for it if coverage is inconsistent?

Many practices encounter a common reality: TBP is often not covered by insurance and may be an out-of-pocket expense.

Rather than treating this as a barrier, leading groups position TBP as an enhanced surveillance service—designed for patients who want longitudinal monitoring, particularly those at elevated risk, with numerous nevi, or seeking objective baselines for peace of mind.

The playbook includes:
• Transparent pricing and informed consent
• A defined cadence (baseline + scheduled follow-ups)
• A documented workflow that keeps the dermatologist as the clinical decision-maker

Positioned clearly and transparently, TBP becomes a patient-directed choice rather than an insurance-dependent offering.

Can we get ROI beyond melanoma surveillance?

Yes—if you choose a platform that stays useful even when the chief complaint isn’t pigmented lesions.

One under-discussed advantage of modern imaging + software ecosystems is that you’re building a visual longitudinal record that can support multiple patient journeys over time with documentation and follow-up that improves patient engagement with before/after comparison from standardized imaging to help your team communicate progress:

• Aesthetics and non-medical dermatology (laser, injectables, resurfacing documentation)
• General dermatology, chronic inflammatory disease progression, clinical research and trials
• Plastic surgery, body contouring, scar evolution
• GLP-1–driven weight loss journeys (body changes over time)
• Patient engagement programs where “seeing change” improves adherence
  
  

DermEngine explicitly supports broader imaging workflows beyond TBP, including aesthetic documentation capabilities and longitudinal tracking features.

Translation for your practice

Whether you’re a single provider or clinic, or a large practice with a national presence, the success criteria are the same:

1. Standardize capture (same poses, same lighting, same training)
   
2. Standardize review (change detection with provider confirmation)
   
3. Standardize governance (thresholds, audit trails, QA checks)
   
4. Repeatable and Scalable (a pathway you can roll out site-by-site without reinvention)
   
   

Why that matters for your practice and network: You’re not just buying capture. You’re buying better clinical signal, less operational noise, and a service patients understand and value that can be replicated with consistent staff training and outputs.

-The MetaOptima Team

Contact us at info@metaoptima.com to meet at the conference or follow us on social media. We look forward to seeing you there!